Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma - Concepedia

Concepedia

Publication | Closed Access

Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma

134

Citations

25

References

2011

Year

Alfredo Berruti, Paola Sperone, Annamaria Ferrero, Antonina Germano, Arianna Ardito, Adriano Massimiliano Priola, Silvia De Francia, Marco Volante, Fulvia Daffara, Daniele Generali,

European Journal of Endocrinology

Abstract

Despite the in vitro activity, sorafenib plus weekly paclitaxel is an inactive salvage treatment in patients with advanced ACC and should not be recommended.

References

	Year	Citations

Page 1